At a Glance: GSK to Buy Out Health-Care JV Stake
March 27 2018 - 9:24AM
Dow Jones News
THE NEWS: GlaxoSmithKline PLC (GSK.LN) has agreed to pay
Novartis AG (NOVN.EB) $13 billion for its 36.5% stake in their
consumer health-care joint venture, moving to consolidate the unit
just three years after it was created.
MARKET REACTION: Shares in both companies rose on news of the
deal. At 1251 GMT, GSK was trading 6.6% higher at GBP13.73 , while
Novartis was up 2.5% at CHF76.24.
THE RATIONALE: The deal makes sense for both companies,
according to analysts at Bryan Garnier.
From Novartis's perspective, the sale is an opportunity to free
up cash to pursue bolt-on acquisitions and fund shareholder
returns, while sharpening its focus on its core pharmaceuticals
business. Chief Executive Vasant Narasimhan, who started on the job
in February, has said he wants to streamline the company's
structure and bolster its pipeline of new drugs.
GSK will receive an immediate earnings boost from the
acquisition, which will increase its exposure to the consumer
health-care business. CEO Emma Walmsley says the deal will give the
company more certainty and provide more flexibility to invest in
research and development of more lucrative drugs.
VALUE FOR SHAREHOLDERS: GSK's adjusted earnings per share for
2018 could rise by as much as 4% on the acquisition, according to
analysts at Jefferies. The deal will also strengthen cash flows,
allowing GSK to raise its dividend, A.J Bell says.
However, the sale will have an immediate dilutive effect on
Novartis's shares, which analysts at Jefferies expect the company
will seek to offset via a buyback program.
WHAT'S NEXT: The transaction is expected to close in the second
quarter. At the same time, GSK says it will begin a strategic
review of its Horlicks brand and other consumer-nutrition products
with a view to raising funds for the purchase.
Looking slightly further ahead, Bryan Garnier expects Novartis
to announce the sale of its eye-care business Alcon by the end of
the year, while CEO Mr. Narasimhan has said he is considering
options for its U.S. generics business.
Write to Nathan Allen at nathan.allen@dowjones.com
(END) Dow Jones Newswires
March 27, 2018 09:09 ET (13:09 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024